• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Intellipharmaceutics (TSX: IPCI )

    N/A UNCHANGED
    Last Price Updated: 10:01 AM EST, Mar 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 0.0700 (10)
    Ask (Size) 0.1200 (20)
    Prev. Close 0.0800
    Today's Range N/A - N/A
    52wk Range 0.0600 - 0.1250
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
    Via ACCESSWIRE
    Intellipharmaceutics Announces Cease Trade Order
    Via ACCESSWIRE

    Performance

    More News

    Read More
    Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
    Via ACCESSWIRE
    Intellipharmaceutics International Inc. Announces Stock Option Grant
    Via ACCESSWIRE
    Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
    Via ACCESSWIRE
    Intellipharmaceutics Announces Third Quarter 2023 Results
    Via ACCESSWIRE
    Intellipharmaceutics Reports Director Election Results
    Via ACCESSWIRE
    Intellipharmaceutics Announces Second Quarter 2023 Results
    Via ACCESSWIRE
    Intellipharmaceutics Announces Third Quarter 2022 Results
    Via ACCESSWIRE
    Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
    Via ACCESSWIRE
    Intellipharmaceutics Announces Second Quarter 2022 Results
    Via ACCESSWIRE
    Intellipharmaceutics Announces Second Quarter 2022 Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Exposures COVID-19
    Intellipharmaceutics Reports Director Election Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Announces First Quarter 2022 Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Announces Fiscal Year 2021 Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Reports Director Election Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Comments on Recent Trading Activity
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Announces Third Quarter 2021 Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Topics Bankruptcy Intellectual Property
    Exposures COVID-19 Financial Intellectual Property
    Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Intellipharmaceutics Announces First Quarter 2021 Results
    From Intellipharmaceutics International Inc.
    Via AccessWire
    Topics Bankruptcy Intellectual Property
    Exposures COVID-19 Financial Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.